Alzheimer's diagnosis beyond cerebrospinal fluid: Probe-Free Detection of Tau Proteins using MXene based redox systems and molecularly imprinted polymers

Biosensors and Bioelectronics X, Journal Year: 2024, Volume and Issue: 20, P. 100513 - 100513

Published: July 6, 2024

Phosphorylated Tau proteins are promising biomarkers for the diagnosis and prognosis of Alzheimer's disease. This study presents a novel voltametric sensor using vanadium MXene polydopamine (V

Language: Английский

Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 5, 2024

ABSTRACT INTRODUCTION Cerebral Amyloid Angiopathy (CAA) is characterized by the deposition of beta-amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ 42/40, phosphorylated-tau (p-tau), neurofilament light chain (NfL) Glial Fibrillary Acidic Protein (GFAP) differ CAA their potential discriminate Boston Criteria 2.0 probable from healthy controls. METHODS Plasma p-tau-181, NfL GFAP were quantified using Simoa 42/40 was also independently immunoprecipitation liquid chromatography mass-spectrometry (IPMS). RESULTS 45 participants with 47 controls had available plasma. ratios significantly lower than While p-tau-181 elevated CAA, similar. A combination (Simoa), resulted an AUC 0.90 (95% CI: 0.80, 0.95). DISCUSSION , those together can

Language: Английский

Zerebrale Amyloidangiopathie

Neurologie up2date, Journal Year: 2024, Volume and Issue: 07(03), P. 265 - 281

Published: Sept. 1, 2024